

**World Dementia
Council** Leading the Global Action
Against Dementia

Global dialogue on clinical trials: Agenda and participants

The dementia landscape project

9 March 2021




Organized in partnership with



Alzheimercentrum Amsterdam
Amsterdam UMC

alzheimer's 
association

Logistics and agenda



Tuesday 9 March 2021


Virtual meeting

08:00 - 09:30 CST Chicago
09:00 - 10:30 EST New York
14:00 - 15:30 GMT London
15:00 - 16:30 CET Central Europe
19:30 - 21:00 IST New Delhi
23:00 - 00:30 JST Tokyo



Section	Speaker(s)
Welcome	Lenny Shallcross
Introductory presentation:	Chair: Professor Philip Scheltens
Challenges and progress in clinical trials	Professor Jeffrey Cummings
Open discussion:	Chair: Dr Maria Carrillo
With opening reflections on Eli Lilly's Donanemab trial as an exemplar of the evolving design of clinical trials	Dr Mark Mintun
Closing remarks	Lenny Shallcross

Co-chairs



Dr Maria Carrillo

Maria Carrillo is chief scientific officer at the Alzheimer’s Association (US), setting the strategic vision for the Association’s global research program. Dr Carrillo has published extensively on early diagnosis and biomarker standardization efforts, as well as on the global challenges to progress for research in Alzheimer’s and dementia. She is a co-author of the “Appropriate Use Criteria for Amyloid Imaging,” published by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer’s Association. Dr Carrillo earned her PhD from Northwestern University’s Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer’s brain imaging and risk factors at Rush University Medical Center in Chicago.





Professor Philip Scheltens

Philip Scheltens is professor of cognitive neurology and director of the Alzheimer Center, Amsterdam University Medical Centers (The Netherlands) and member of the World Dementia Council. His main clinical and research interests are Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national principal investigator for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 70 PhD theses have appeared since. In 2013, he co-founded the Dutch national plan against dementia (Deltaplan Dementie) and serves as the chair of its board.




Speakers



Professor Jeffrey Cummings

Jeffrey Cummings, MD, ScD, is Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health. He is the Joy Chambers- Grundy Professor of Brain Science, Vice Chair for Research, and Director of the Chambers- Gundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). Dr Cummings is a world- renowned Alzheimer's researcher and leader of clinical trials. He has been recognized for his research and leadership contributions in the field of Alzheimer's disease through the Henderson Award of the American Geriatrics Society (2006), the Ronald and Nancy Reagan Research Award of the national Alzheimer's Association (2008), and the Lifetime Achievement Award of the Society for Behavioral and Cognitive Neurology (2017). In 2010, he was honored by the American Association of Geriatric Psychiatry with their Distinguished Scientist Award. In 2018, he was honored with the Leadership and Achievement Award by the International Society of CNS Drug Development, and he received the Bengt Winblad Lifetime Achievement Award from the national Alzheimer's Association. In 2019, the International Psychogeriatric Association awarded him with the Distinguished Service Award and he received the Alzheimer's Drug Discovery Foundation's Melvin R. Goodes Prize that honors an innovative researcher who has made a significant and lasting impact in the field.





Dr Mark Mintun

Mark Mintun, M.D., has been the Vice-President of Pain and Neurodegeneration Research and Clinical Development since January of 2018. In 2010, Dr. Mintun joined Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly & Company, as Chief Medical Officer and became its President in 2014. Prior to Avid, Dr. Mintun was Professor and Vice-Chair of Radiology at the Washington University School of Medicine, with joint appointments in Psychiatry, Neurology, Bioengineering, and the Anatomy and Neurobiology Departments. He earned a BS in Chemical Engineering from the Massachusetts Institute of Technology in 1977, received his medical degree in 1981 at Washington University School of Medicine and completed a research fellowship in neurology and residency training in nuclear medicine. Dr. Mintun has co-authored over 200 research publications that include reports of brain imaging to characterize flow/metabolism relationships, neurotransmitter systems, circuitry for processing affective stimuli and the pathology of neurodegenerative diseases. More recently he has led development programs for both amyloid and tau imaging of patients with neurodegenerative diseases.




Lenny Shallcross

Lenny Shallcross is executive director at the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society he worked in the UK government as a political adviser at DCMS and the DoH, as well as working in Parliament and for the Labour Party.



Discussion participants



Professor Ricardo Allegri

Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre, FLENI


Professor Ricardo F. Allegri is Head of the Department of Cognitive Neurology, Neuropsychiatry and Neuropsychology and Director of the Ageing and Memory Centre at the Neurological Research Institute Raúl Carrea (FLENI) in Buenos Aires. He is also Professor of Neurology in the School of Medicine at the University of Buenos Aires and is chair of the Scientific Council at the Association against Alzheimer's disease and related disorders in Argentina (ALMA). Professor Allegri has published extensively on cognitive neurology in neurological journals and books and has co-edited seven books, including, "Dementia: A Multidisciplinary Approach," one of the most important books written in Spanish on this topic. He has received over 45 awards in the field of Cognitive Neurology and Neuropsychiatry, including the National Academy of Medicine Award in 2006 and the Research Recognition Award by the School of Medicine, University of Buenos Aires in 2014.



Professor Clive Ballard

Pro-Vice-Chancellor and Executive Dean, College of Medicine and Health, University of Exeter

Clive has led or co-authored well over 600 research papers. He received the prestigious Weston Brain Institute International Outstanding Achievement Award 2019. His main research specialisms are drug discovery, dementia prevention, improving care for people with dementia in residential homes. He is also an expert in Lewy Body Dementia and Parkinson's Disease Dementia, and is an advocate of better prescribing and treatment pathways to improve outcomes for individuals. Before joining Exeter, Clive held directorship roles at King's College London Institute of Psychiatry and at the Alzheimer's Society. He was pivotal in the successful campaign to overturn a NICE decision and make anti-dementia drugs available for people with dementia. Clive is part of a growing team of outstanding researchers at the College of Medicine and Health, which is recruiting high-calibre academics and significantly expanding



educational programmes and student numbers. In the last year, the College has reached the Leiden ranking's world top 20 for the quality of its Health and Biomedical Science research, attracted a £10 million donation from the Dennis and Mireille Gillings Foundation, launched a new Academy of Nursing and received permission to expand Medicine student numbers.



Professor Howard Bergman

Professor of Family Medicine, Medicine (Geriatrics), and Oncology, McGill University


Dr Howard Bergman is Professor of Family Medicine, Medicine (Geriatrics), and Oncology, and Assistant Dean, International Affairs, Faculty of Medicine, McGill University. In 2009, at the request of the Quebec Minister of Health, he authored the Quebec Alzheimer Plan and is presently working with the Quebec ministry of health and social services on its implementation. He co-created and co-leads with Professor Isabelle Vedel, the Canadian team for healthcare services/system improvement in dementia care (ROSA research team). In 2018-19, he chaired the Canadian Academy of Health Sciences Panel of 6 experts for the Assessment of Evidence and Best Practices for the development of a Canadian Dementia Strategy, assembled at the request of Public Health Agency of Canada.



Dr Tobias Bittner

Biomarker Leader for the Alzheimer's disease (AD) Franchise at F.Hoffmann-LaRoche

Dr. Bittner is a trained neuroscientist, with a history of more than 15 years in developing therapeutics, diagnostics, and biomarkers in neuroscience in pharma and diagnostic industry and academia. Currently, Dr. Bittner serves as the Biomarker Leader for the Alzheimer's disease (AD) Franchise at F.Hoffmann-LaRoche and Genentech with the goal to evaluate and apply state-of-the-art fluid, imaging, genetic, and digital biomarkers to molecules in pre-clinical and clinical development and to transform the diagnostic pathway in Alzheimer's disease.



Professor Sandra Black

Professor of Medicine
(Neurology) at
Sunnybrook HSC,
UToronto


Sandra E Black, O.C., O.Ont., Hon.DSc.,MD, FRCP(C), FRSC, FANA, FAHA, FAAN is a Professor of Medicine (Neurology) at Sunnybrook HSC, UToronto. An internationally known cognitive neurologist, she has actively engaged in stroke and dementia trials for 30 years. Inaugural Director, Toronto Dementia Research Alliance (2012-20) , she has directed Sunnybrook's Hurvitz Brain Sciences Research Program (2006-) and became Scientific Director, Dr. Sandra Black Centre for Brain Resilience and Recovery (2020-), funded for \$10M by anonymous donation. Her research career bridges dementia and stroke, using standardized neuroimaging, genetic, clinical and cognitive measures to elucidate brain-behavior relationships, with recent focus on Alzheimer/Small Vessel Disease interactions. Publications: 709 papers (70 invited) (Google HI 120; >67,000 citations). Recognitions include: Dean's UofT Lifetime Achievement Award, U of Waterloo Honorary Doctorate, Lifetime Achievement Award, AAN's Society of Cognitive and Behavioural Neurology, Appointment as Member, Order of Ontario (2012) and Officer, Order of Canada (201) citing contributions to Alzheimer's disease, stroke and vascular dementia.



Dr Rob Buckle

Chief Science Officer at
the Medical Research
Council

Dr Rob Buckle is Chief Science Officer at the Medical Research Council (MRC), which is part of UK Research and Innovation (UKRI) and the main Government agency responsible for UK biomedical research. MRC invests ~£800m each year on world-class research across the biomedical spectrum. As CSO, Rob oversees MRC's scientific operations and funding procedures, major science initiatives and strategic funding partnerships. In relation to dementias research, Rob has been a major contributor to the development of the UK Government's strategic approach to this area and provided oversight for the establishment of the UK Dementia Research Institute and the MRC Dementias Platform UK. Internationally, Rob has served as a founder member on the Executive Boards for both the EU's Joint Programming Initiative in Neurodegeneration (JPND) and the




Centres of Excellence in Neurodegeneration (COEN) initiative, and chaired the OECD working group on big data in dementia research between 2014/15.



Fiona Carragher

Director of Research and Influencing, Alzheimer's Society (UK)

As Alzheimer's Society's Director of Research and Influencing, Fiona plays a pivotal role in the Society vision to create a world without dementia. Fiona has overall responsibility for our Research and Influencing strategy; leading our growing and ambitious world-class research programme and portfolio and our work to strengthen our position as the national charity leader on dementia health, social care policy and societal change. Prior to joining Alzheimer's Society, Fiona was the Deputy Chief Scientific Officer for NHS England, providing leadership for the 50,000 healthcare science professionals in the NHS and expert advice to the health system on science, innovation and diagnostics. She led a broad portfolio of policy responsibilities including establishing the UK Antimicrobial Resistance Diagnostics programme and the system wide Action Plan on Hearing Loss. She is a passionate advocate for women in health and led the establishment of the first Women in Science and Engineering fellowship programme in the NHS. Fiona is committed to ensuring that we reach every person who has a dementia diagnosis and wants our help. She wants to change the conversation on dementia, mainstream the rights of people affected by dementia and drive the research agenda, working tirelessly to improve care and find a cure.



Dr Christopher Chen

Associate Professor,
National University of
Singapore


Dr Christopher Chen is a Senior Clinician-Scientist at the Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, and Director of the Memory Aging and Cognition Centre. His early medical and research training was at Cambridge, Oxford and the Institute of Neurology, London. Since returning to Singapore, Dr Chen has developed multi-disciplinary research programmes with extensive international collaborations. His major research and clinical interests are in neuroimaging, molecular biology and treatment of stroke and dementia. He has published over 390 peer reviewed papers, is the PI for several studies with cognitive outcomes, serves on journal editorial boards and has been a member of trial steering committees and advisory panels. Currently he is President of the Asian Society Against Dementia, Secretary-Treasurer of the Asian & Oceanian Association of Neurology and past-chair of the International Society for Vascular Behavioural and Cognitive Disorders.



Dr Howard Chertkow

Director, Kimel Family
Centre for Brain Health
and Wellness, Baycrest

Dr Howard Chertkow joined Baycrest and the University of Toronto from Montreal's McGill University, where he served as Director of the Jewish General Hospital (JGH) and McGill University Bloomfield Centre for Research in Aging and was a Senior Investigator in the Lady Davis Institute for Medical Research. In his practice at the JGH, Dr Chertkow diagnosed and treated patients with early stage Alzheimer's disease and other dementias, and helped found and direct Canada's largest memory clinic. Dr Chertkow will direct the new Kimel Family Centre for Brain Health and Wellness, a research, education and clinical interdisciplinary program to develop and evaluate the most promising approaches to preventing cognitive decline. As its inaugural Director, Dr Chertkow will assemble a state-of-the-art Clinical Trials Unit and further develop Baycrest's translational research program in dementia to test the latest emerging therapies for Alzheimer's disease and related conditions. He will also serve as a Clinical Advisor to the Centre for Aging + Brain Health Innovation (CABHI), the largest venture of its kind in the global seniors' care sector.



Professor Bart De Strooper

Director, UK Dementia Research Institute, Professor and VIB researcher, KU Leuven, Belgium and UCL, London


Bart De Strooper, MD, PhD is director of the Dementia research Institute of the UK and professor of molecular medicine at the VIB Centre for Brain and Disease research University of Leuven and Professor at University College London. His scientific work is focused on the understanding of the fundamental mechanisms that underlie Alzheimer's and Parkinson's disease. His major finding is the identification of gamma-secretase and its role in the proteolysis of the amyloid precursor protein and in Notch signaling, for which he received the Brain Prize 2018 together with Hardy, Goedert and Haass. Recently he has reoriented his work to the understanding of the cellular phase of Alzheimer's disease. His aim is to understand the mechanisms of resilience that make that some people survive into very old age with the biochemical signs of Alzheimer's Disease but without the symptoms of dementia. He has published close to 400 papers with h-index of 121 and is recognized as highly cited researcher 2018, 2019 and 2020 (Clarivate, Web of Science Group). Expertscape considers him World Expert in Alzheimer's disease (no 8 worldwide), Presenilins (no 1 worldwide) and Amyloid beta-Peptides (no 4 worldwide)."



Professor Sebastiaan Engelborghs

Professor of neurology and neurosciences at Vrije Universiteit Brussel

Sebastiaan Engelborghs is full professor of neurology and neurosciences at Vrije Universiteit Brussel (VUB), co-director of the VUB Center for Neurosciences (C4N) and chairman of the neurology department of the VUB university hospital (UZ Brussel). He as well is full professor of neurosciences and neurochemistry at University of Antwerp. Sebastiaan Engelborghs is board certified in clinical neurology (2001) and neurological revalidation medicine (2009). He achieved a PhD in medical sciences in 2004 and has interdisciplinary expertise in clinical neurology and neurosciences, including electrophysiology, neuro-imaging, biochemistry, neurogenetics and neuropathology. Both clinically and with regard to research, he is specialized in neurodegenerative brain disorders that cause dementia. He has built up expertise in clinical trials for AD and related disorders for more than 20 years, and was PI as well as



national or global coordinating physician for several clinical trials, as well as being involved in the design of some of these clinical trials. Sebastiaan Engelborghs is (co-)author on 330 PubMed-cited papers in international peer-reviewed journals and 17 book chapters which results in 19.326 citations without self-citations, and a WoS h-index of 64 (February 22, 2021)."



Franca Gatto

Director of the Aging, Seniors and Dementia Division, Centre for Health Promotion at the Public Health Agency of Canada


Franca Gatto is the Director of the Aging, Seniors and Dementia Division in the Centre for Health Promotion at the Public Health Agency of Canada, a position she has held since September 2017. Franca works with stakeholder organizations and provincial and territorial governments across Canada, and is the federal government focal point for health issues affecting Canada's older adult population. Through federal investments, partnerships and policy leadership, the Division of Aging, Seniors and Dementia seeks to promote healthy aging in the areas of dementia, injury prevention, and mental health. Franca and her team is responsible for the development of Canada's first national dementia strategy, A Dementia Strategy for Canada: Together We Aspire, launched in 2019. Along with her team she is spearheading the implementation of the national dementia strategy and is administering federal investments of \$70M over five years to support key components of the strategy.



Professor Serge Gauthier

Director, Alzheimer's Disease Research Unit at the McGill Centre for Studies in Aging, McGill University

Dr Serge Gauthier is Director of the Alzheimer's disease Research Unit at the McGill Centre for Studies in Aging, McGill University and a Professor at the University's Neurology and Neurosurgery, Psychiatry and Medicine Departments. He was formerly Clinical Investigator and Staff Neurologist at the Montreal Neurological Hospital and Institute, Director of the McGill Centre for Studies in Ageing and Research Chair at the Canadian Institute for Health Research. His research interests include etiology and treatment of Alzheimer's disease and other related diagnosis and development of consensus guidelines on approval and use of antidementia drugs, and on the rights of persons with dementia



to participate in research. Main publications are Clinical Diagnosis and Management of Alzheimer's Disease (2006), Alzheimer's Disease in Primary Care (1997) and Pharmacotherapy of Alzheimer's Disease (1998).



Professor Frank Gunn-Moore

Professor of Molecular Neurobiology, University of St Andrews


I am a molecular neurobiologist who studies the development and survival of mammalian neurons. My approach to achieve this has been to combine all three science disciplines, publishing in biological, chemical and physics-based journals. We have made discoveries in understanding the early stages of Alzheimer's disease, pioneering new models and identified potential therapeutic targets. In addition, we have developed novel optical technology that allows the manipulation and imaging of cells including the airy-beam light sheet microscope. At the University of St Andrews, I am the Head of the School of Biology (400 staff, 700 students). Externally, I am Deputy Director of the Scottish Universities Life Sciences Alliance which previously helped to develop the European Lead Factory and the National Phenotypic Screening Centre. I have sat on many different funding agencies. More recently, I have led the Fundamental Sciences in the Scottish Dementia Research Consortium, and sit on the Scottish Government Cross Party committee in the Life Sciences.



Dr Christian Haass

Head of the Laboratory of Neurodegenerative Disease Research, University of Munich

Christian Haass graduated in Molecular Biology at the University of Heidelberg, Germany. He was a postdoc and assistant professor of Neurology at the Harvard Medical School in the institute of Dr. Dennis Selkoe. Since 1999 he is the head of the division of Biochemistry at the Ludwig-Maximilians University and since 2009 he is also the speaker of the German Center for Neurodegenerative Diseases (DZNE) in Munich. Dr. Haass received a number of prestigious awards, among them, the Gottfried Wilhelm Leibniz-Award of the Deutsche Forschungsgemeinschaft, the Potamkin Award of the American Academy of Neurology, the MedLife award, an ERC advanced grant, and most recently the brain prize. Dr. Haass is



the speaker of the Munich Cluster of Systems Neurology (SyNergy). Christian's lab made major contributions to the understanding of the cellular mechanisms involved in a number of neurodegenerative diseases, such as Alzheimer's disease, Frontotemporal lobar degeneration and Amyotrophic lateral sclerosis. His lab provided major insight into the mechanisms of A β generation and the biological functions of the secretases. The Haass lab also identified cellular mechanisms affecting nuclear transport of nucleic acid binding proteins in genetic variants of ALS. Currently, the Haass lab has a strong focus on microglial function and dysfunction in AD. This also includes the development of therapeutic strategies allowing to modulate protective functions of microglia.



Professor Oskar Hansson

Professor of Neurology,
Lund University


Oskar Hansson is a neurology professor at Lund University and serves as a consulting neurologist at Skåne University Hospital (Sweden). During the last 20 years, Professor Hansson has conducted clinical and translational research focusing on the earliest phases of Alzheimer's. He has built a creative and multi-disciplinary research team and leads the Swedish BioFINDER study. His research combines the study of well characterized patient cohorts with state-of-the-art biomedical and biophysical techniques, most notably in brain imaging. Professor Hansson earned his doctorate in neurobiology, his medical degree, and additional training as a neurology specialist at Lund University.



Professor David Holtzman

Andrew B. and
Gretchen P. Jones
Professor

Dr. Holtzman is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, and a member of the Hope Center for Neurological Disorders. A major interest in my lab is in understanding basic mechanisms underlying acute and chronic cell dysfunction in the CNS particularly as these mechanisms may relate to Alzheimer's disease (AD) and injury to the developing brain.



Professor Clifford Jack

Professor of Radiology,
Mayo Clinic


Clifford R. Jack, Jr., M.D., is a professor of Radiology, and the Alexander Family Professor of Alzheimer's Disease Research at the Mayo Clinic, Rochester MN. A major research focus is modeling the temporal trajectory of Alzheimer's disease biomarkers (MRI, tau PET, amyloid PET imaging and biofluids) in relation to clinical symptoms. His research group serves as the central MRI lab for a number of national and international observational and therapeutic studies in Alzheimer's disease including ADNI, A4, A345, ARIC



Ivan Koychev

Clinical academic
psychiatrist,
University of Oxford

Ivan Koychev is a clinical academic psychiatrist at the University of Oxford with a focus on the development of treatments for neurodegenerative disorders. His research experience spans the key components of neuroscience clinical trial methodology: conduct of proof-of-concept (PoC) biomarker-based clinical trials in surrogate populations, testing of repurposed compounds, development of stratification and efficacy biomarkers and creation of infrastructure for large-scale stratified recruitment into preclinical dementia experimental medicine studies and clinical trials. He has a particular interest in the development of scalable biomarkers for the detection of preclinical Alzheimer's disease using digital technologies, blood biomarkers and longitudinal health data. Clinically, he works as a Consultant Neuropsychiatrist focusing on the assessment and management of patients with neuropsychiatric presentations in acute medical settings.



Dr Giovanna Lalli

Director of Scientific
Affairs, UK Dementia
Research Institute


Giovanna Lalli is the Director of Scientific Affairs of the UK Dementia Research Institute (UK DRI - <https://ukdri.ac.uk/about-us>), working on strategic development and partnerships, scientific initiatives, training/ career development activities. Giovanna holds MSc degrees in Chemistry and Pharmaceutical Technology (University of Bologna) and in Molecular Biology (University of Southern California). She obtained a PhD in Cell Physiology from University College London and has nearly 20 years of research experience, including a seven-year period as principal investigator and lecturer in molecular neurobiology at King's College London. Giovanna joined the UK DRI in September 2018, following three years as Senior Portfolio Developer at Wellcome overseeing the cellular and molecular neuroscience portfolio, supporting applicants and award holders, interacting with a wide range of UK and international stakeholders. While at Wellcome Giovanna also served for ten months as Acting Head of Neuroscience and Mental Health, developing new strategic funding initiatives in neuroscience research.



Professor Virginia Lee

Professor of Pathology,
University of
Pennsylvania

Dr. Virginia M.-Y. Lee studied music at the Royal Academy of Music in London (1962-1964) and received her PhD in Biochemistry from the University of California at San Francisco in 1973. She joined the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine in 1981 and rose to become Professor of Pathology & Laboratory Medicine in 1989. Dr. Lee identified tau, alpha-synuclein and TDP-43 as disease proteins that form unique inclusions in Alzheimer's, Parkinson's and frontotemporal degeneration/Lou Gehrig's disease, respectively, and has advanced understanding of their roles in these disorders. Dr. Lee's h-index is 199 and she is listed among the 10 most highly cited AD researchers from 1985-2008 and among the top 400 most highly influential biomedical researchers from 1996-2011. ISI has recognized Dr. Lee as an ISI Highly Cited Researcher and places her in the top 10 most highly cited neuroscientists from 1997 to 2007.



Professor Allan Levey

Professor and Chair of the Department of Neurology at Emory University and Director of the Goizueta Alzheimer's Disease Research Center


Dr. Allan Levey is Professor and Chair of the Department of Neurology at Emory University and Director of the Goizueta Alzheimer's Disease Research Center. Dr. Levey is a neurologist and neuroscientist internationally recognized for his work in neurodegenerative disease, with more than 400 research publications. His work in Alzheimer's Disease and related neurodegenerative disorders has contributed to understanding mechanisms involved in these conditions and translation to new therapeutic strategies and biomarkers. He leads multi-institutional teams in NIH translational programs, including Accelerating Medicine Partnership for Alzheimer's Disease and the TREAT-AD consortia. He currently serves as Co-Chair of the Department of Health and Human Services National Alzheimer's Project Act (NAPA) Advisory Council on Alzheimer's Research, Care and Services and Chair of the Clinical Task Force for the NIA Alzheimer's Disease Research Center program.



Casey Lynch

President and Chief Executive Officer, Cortexyme

Casey C. Lynch has served as President and Chief Executive Officer and a member of the board of directors of Cortexyme since July 2014, and as Chairman of the board of directors since November 2018. Prior to co-founding Cortexyme, Ms. Lynch co-founded and led various companies and organizations in the biotechnology industry including Aspira Biosystems, Inc. and NeuroInsights, LLC. She served as Aspira's co-founder, President and Chief Executive Officer from 1999 to 2004 and she co-founded NeuroInsights, LLC and served as its Managing Director from 2004 to 2015. Ms. Lynch also co-founded the Neurotechnology Industry Organization and served as a board member from March 2005 to September 2018. Ms. Lynch oversaw toxicology screening and evaluated new product opportunities at Centaur Pharmaceuticals, including multiple sclerosis, arthritis, and uveitis. Ms. Lynch conducted preclinical testing for Alzheimer's disease treatment at the Wadsworth Medical Center and researched the neurological basis of schizophrenia and epilepsy at UCLA. Her graduate work on neurotrophic factor cell



biology and neurodegenerative diseases, was carried out at UCSF and Stanford University. Ms. Lynch holds a B.S. in Neuroscience from the University of California, Los Angeles, an M.S. in Neuroscience from the University of California, San Francisco.



Professor Clare MacKay

Professor of Imaging Neuroscience and leads the Translational Neuroimaging Group in the Department of Psychiatry, University of Oxford


Clare Mackay is a Professor of Imaging Neuroscience and leads the Translational Neuroimaging Group in the Department of Psychiatry, University of Oxford. Her group use neuroimaging techniques to understand risk and develop markers for psychiatric and neurodegenerative disease. She trained in Psychology at the University of Liverpool, where she also studied for her PhD in quantitative MRI. Clare is Associate Head of Department for IT/IG, and Associate Director of the Oxford Centre for Human Brain Activity (OHBA) She is a theme lead for the NIHR Oxford Health Biomedical Research Centre (Older Adults & Dementia), where she is leading the development of a new 'Brain Health Centre' for memory clinic patients. For the MRC Dementias Platform UK (DPUK) Clare led the development of imaging informatics infrastructure, to facilitate data management, sharing and processing for imaging data relevant to dementia research. She also leads the Open Neuroimaging Theme of the new Wellcome Centre for Integrative Neuroimaging.



Dr Georgina MacKenzie

Portfolio Manager within the Neuroscience and Mental Health team at the Wellcome Trust

Dr Georgina MacKenzie is a Portfolio Manager within the Neuroscience and Mental Health team at the Wellcome Trust. Georgina has been at Wellcome since 2016 where she oversees the cellular and molecular neuroscience portfolio. In addition to managing a diverse research portfolio she develops and implements strategic initiatives and builds effective relationships with stakeholders within the global neuroscience and mental health community. Georgina has a strong interest in translating promising research to the clinic and was previously on secondment to Wellcome Innovations. A biochemist and neuroscientist by training, Georgina is a graduate of the University of Bath, UK and




earned her MRes and PhD from Imperial College London, UK. She completed postdoctoral training at Tufts University in Boston, Massachusetts followed by a second postdoctoral position within industry.



Dr Husseini Manji

Global Head,
J&J Science for Minds

Husseini K Manji, MD, FRCPC is Global Head, J&J Science for Minds, and immediate past Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Johnson & Johnson pharmaceutical companies. His research has investigated disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. This has led to the FDA approval of the first novel antidepressant mechanism (NMDA-antagonism) in decades and has been actively involved in developing biomarkers to help refine these diseases. Dr Manji has been inducted into the National Academy of Medicine, the World Economic Forum Global Future Councils and is a member of Harvard/MIT's Stanley Center SAB, amongst other appointments. He has received a number of awards including the NIMH Director's Career Award for Significant Scientific Achievement, and has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and development of novel therapeutics with over 300 publications in peer-reviewed journals, including Science and Nature Neuroscience. He is an Honorary Fellow at Oxford University and Visiting Professor at Duke University, and previously served as Chief of the Laboratory of Molecular Pathophysiology at the NIH as well as Director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world.



Dr Eliezer Masliah

Director of the Division of Neurosciences, NIA/NIH


Dr Masliah joined the NIA/NIH as Director of the Division of Neurosciences in the summer of 2016. before joining NIA he held joint appointments as tenured track Professor at the Departments of Neurosciences and Pathology and as Director of the Autopsy Service at UCSD. As head of UCSD's Experimental Neuropathology Laboratory, he investigated mechanisms of synaptic damage in AD, PD and other neurodegenerative disorders, was involved with the discovery of α -synuclein and developed novel models as well as new gene experimental immunotherapies. Four of the experimental therapeutic approaches developed at his laboratory targeting α -synuclein have now passed Phase I clinical trials.



Dr Pierre Meulien

Executive Director, Innovative Medicines Initiative (IMI)

Dr Pierre Meulien is executive director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. At IMI, he is responsible for the overall management of the program, which works to improve and accelerate the drug development process by facilitating collaboration between the key players involved in health research. Previously, Dr Meulien was president and CEO of Genome Canada, where he raised money and oversaw the launch of novel projects and networks in the field of genomics-based technologies. Prior to that, he was chief scientific officer for Genome British Columbia and was the founding CEO of the Dublin Molecular Medicine Center. Dr Meulien also worked with the French biotechnology company Transgene and with Aventis Pasteur (now Sanofi Pasteur). He has a Ph.D. in molecular biology from the University of Edinburgh and carried out a postdoctoral fellowship at the Institut Pasteur in Paris.



Dr José Molinuevo

Vice President in
Clinical Development
Neurodegeneration,
Lundbeck


José L. Molinuevo (MD, PhD), neurologist; his clinical work and research activities are related with neurodegenerative diseases, mostly Parkinson and Alzheimer's disease (AD) and related disorders. He undertook his MD degree at the University of Valencia, his neurology training at Hospital Clinic in Barcelona, and his PhD, on Parkinson's disease, at the University of Barcelona. He started (2001) and directed a genetic counseling program for monogenic dementias (PICOGEN), which is now part of DIAN and DIAN-TU- He also directed the Alzheimer's disease and other cognitivedisorders unit at the Hospital Clinic de Barcelona from 2003 until 2016. Later, he joined the BarcelonaBeta Brain Research Center (BBRC), where he was the Scientific Director of the Alzheimer Prevention Program and University Pompeu Fabra in 2018 as associate professor. He started the ALFA program and several other international projects at BBRC, which has become a leading center on Alzheimer's disease (AD) prevention from a clinical, cognitive, genetic, and biomarker, including fluid and neuroimaging, perspective. Recently, he joined Lundbeck as Vice President in clinical development neurodegeneration.



Dr Cath Mummery

Consultant neurologist
leading the Cognitive
Disorders Service at
the National Hospital
for Neurology and
Neurosurgery.

Cath Mummery is a consultant neurologist, and leads the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery. She is head of clinical trials at the Dementia Research Centre, University College London and has been chief investigator on over 20 early phase drug trials of potential disease modifying agents, including the ground-breaking platform trial DIAN-TU in presymptomatic individuals at risk of familial AD, and a first-in-human antisense oligonucleotide study, targeting MAPT to reduce tau in AD. She has a particular interest in early phase studies and genetic therapies, and in the psychological impact of trial participation. She sits on a number of advisory boards for potential disease modifying agents and for dementia service development. She is deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to the conduct



of early phase trials in neurodegeneration.
"Special appointed lecturer, Unit for early and exploratory clinical development, University of Tokyo.



Dr Yoshiki Niimi

Specially appointed lecturer, University of Tokyo


Dr Niimi participates in the Japanese TRC-PAD (J-TRC) and the DIAN-Japan as a site PI at Tokyo university. He had worked at the Ministry of Health, Labour, and Welfare Japan as a senior specialist for dementia from 2012 till 2015. During that period, the G8 Dementia Summit and serial legacy events were held. He played a pivotal role in promoting the Global Dementia Legacy Event Japan and formulating the Japanese national dementia plan or 'New orange plan'. By utilizing this experience, he serves as the Vice-chair of the Social problem committee of the Japan Society for dementia research. "



Professor Ricardo Nitrini

Professor of Neurology, University of São Paulo Medical School


Ricardo Nitrini is a clinical neurologist with expertise in Behavioral and Cognitive Neurology. His academic career has been developed in the University of São Paulo Medical School, from graduation to full professor of Neurology. In the first years of his academic career he was strongly linked to teaching neurology and publishing books and chapters on books for undergraduate students. His initial areas of research were on infectious diseases such as neurosyphilis, neurosyphilis associated with HIV and prion diseases. Although he had published papers on behavioral and cognitive neurology from the beginning of his academic activities, only later on his research became more focused on epidemiological studies in dementia and in the diagnosis of dementia in low educated individuals. Among his most relevant contributions are tests designed for the diagnosis of cognitive impairment of illiterate and low educated individuals.



**Dr Richard
Oakley**

Head of Research,
Alzheimer's Society
(UK)

Richard joined Alzheimer's Society on 7 September 2020. As Head of Research, Richard plays a critical role in the development and implementation of Alzheimer's Society's Research Strategy; working with the Director of Research and Influencing to lead our growing and ambitious world class research programme and portfolio. In particular, Richard heads up our Research Grants, Research Communications and Research Engagement teams. Together, they aim to ensure we provide essential funding and support to researchers, continue to engage people affected by dementia and communicate key milestones and developments in research across our networks and to the wider population. Prior to joining Alzheimer's Society, Richard worked for eight years at Cancer Research, most recently as Head of Research Information and Communications. In this role, Richard led on the implementation of a new communications strategy underpinned by audience insight and focused on delivering the maximum impact for organisational priorities. With his leadership, his team created an online platform to supply fundraisers with the best, most strategic examples of research content, to empower them to have better conversations with high value and mass audiences. Prior to this, Richard worked across multiple teams at Cancer Research as a Senior Research Funding manager; ensuring they funded the best research and researchers via response mode, core funding and fellowship funding streams. Richard is a biochemist by background, completing his PhD in biochemistry at Bristol University before undertaking his post doctorate in Tissue Engineering at the EPFL, Switzerland.



Dr Niels Prins

Director,
Brain Research Center


Dr Niels Prins has been the director of the Brain Research Center (BRC), a platform of research centers specialized in testing new drugs for Alzheimer's and other brain diseases, since 2012. In addition, he has been working part-time since 2009 as a neurologist at the Alzheimer Center Amsterdam of the Amsterdam UMC. He graduated in 1998 at the University of Amsterdam. He obtained his PhD in 2004 with the thesis "Cerebral small vessel disease in dementia and depression" at Erasmus University Rotterdam and obtained a Master of Science in Clinical Epidemiology at NIHES in 2003. From 2004-2009 he followed a neurologist training at Erasmus MC.



Dr Gil Rabinovici

Edward Fein and
Pearl Landrith
Distinguished
Professor,
Departments of
Neurology and
Radiology,
University of California
San Francisco (UCSF)

Dr Gil Rabinovici is the Edward Fein and Pearl Landrith Distinguished Professor in the University of California San Francisco (UCSF) Departments of Neurology and Radiology. He received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed neurology residency and behavioral neurology fellowship training at UCSF. Dr Rabinovici's research focuses on utilizing multi-modal neuroimaging techniques and other biomarkers to improve early detection and diagnostic accuracy in dementia, and to study mechanisms of neurodegenerative diseases. He is Associate Director of the UCSF Alzheimer's Disease Research Center, serves as Study Chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies and co-PI of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS), among other activities. Dr Rabinovici's work is supported by the National Institutes of Health, the Alzheimer's Association, the American College of Radiology, the Rainwater Charitable Foundation and industry partners. Awards recognizing his work include the 2015 Christopher Clark Award for Advancement of the Field of Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 de Leon Prize from the Alzheimer's Association.



**Dr Vijayalakshmi
Ravindranath**

Founder director,
Centre for Brain
Research, Indian
Institute of Science


Dr. Vijayalakshmi Ravindranath obtained her Ph.D from the University of Mysore in 1981. In 1986, after completing her post-doctoral training at the National Institutes of Health, USA, she joined the Department of Neurochemistry at National Institute of Mental Health and Neurosciences, (NIMHANS) Bangalore. In 1999, the Dept. of Biotechnology (DBT), Government of India sought her out to help establish the National Brain Research Centre (NBRC), an autonomous institution of DBT, Ministry of Science and Technology as a centre of excellence and to co-ordinate and network neuroscience research groups in the country. She continued as Founder Director, NBRC till May 2009, when she returned to Bangalore at the Indian Institute of Science (IISc) as Professor and Founder Chair of the newly created Centre for Neuroscience. She is currently Founder Director, Centre for Brain Research (CBR) at Indian Institute of Science. The newly established Centre for Brain Research is a unique public-private partnership between IISc (a public funded institution) and Pratiksha Trust (a philanthropy) that funds CBR. Research at CBR is focused on aging brain and a large, prospective longitudinal study of 10,000 ageing individuals has been initiated for the first time in India. In addition, she has received generous funding from Tata Trusts, which has paved the way for starting a longitudinal study in an urban cohort.



**Professor
William
Reichman**

President and Chief
Executive Officer,
Baycrest

Dr. William E. Reichman is President and Chief Executive Officer of Baycrest, among the world's premier academic health care organizations focused on seniors health and residential care and aging brain function. Dr. Reichman has an appointment as Professor of Psychiatry on the Faculty of Medicine at the University of Toronto and is a recipient of an honorary degree of laws from OCAD University. He is a noted global authority on the delivery of innovative medical, mental health and dementia services in geriatric care settings. Dr. Reichman is currently President of the International Psychogeriatric Association and has advised the World Health Organization and the governments of Canada, the United States and China on health policy.




He is Co-Chair of Canada's Ministerial Advisory Board on Dementia and has been instrumental in the development of Canada's National Dementia Strategy.



Professor Eric Reiman

Executive director, Banner Alzheimer's Institute and chief executive officer, Banner Research

Eric Reiman is executive director of the Banner Alzheimer's Institute, chief executive officer of Banner Research, clinical director of Neurogenomics at the Translational Genomics Research Institute, professor of psychiatry at the University of Arizona, university professor of neuroscience at Arizona State University, and director of the Arizona Alzheimer's Consortium. He is leading the Platform for the Discovery of Alzheimer's Disease Mechanisms and Treatments project. Reiman and his Banner Alzheimer's Institute colleagues, Pierre Tariot and Jessica Langbaum, lead the Alzheimer's Prevention Initiative (API), which has helped to introduce a new era in Alzheimer's prevention research. He is the author of more than 300 publications, a principal investigator of several large NIH grants and a recipient of the Potamkin Prize. Reiman is internationally recognized for his pioneering contributions in brain imaging, genomics, and the cognitive and behavioral neurosciences; the unusually early detection and tracking of Alzheimer's disease; and the accelerated evaluation of Alzheimer's prevention therapies. He and his colleagues hope to provide the evidence needed to help establish a new national standard of dementia care by 2020 and to find and support the approval of effective Alzheimer's prevention therapies by 2025. They continue to find new ways for researchers from different disciplines and organizations to work together in support of their ambitious goals.



Professor Martin Rossor

NIHR National Director for Dementia Research, UCL Queen Square Institute of Neurology


Martin Rossor is the NIHR National Director for Dementia Research, Professor Emeritus, and Principal Research Associate at the UCL Queen Square Institute of Neurology. Following his training in clinical neurology at the National Hospital, Queen Square, Martin undertook primary research on the neurochemistry of degenerative dementia at the MRC Neurochemical Pharmacology Unit, Cambridge, before being appointed as Consultant Neurologist at St. Mary's Hospital London and the National Hospital in 1986. Martin was appointed as the Chairman of the Division of Neurology in 2002, after becoming Professor of Clinical Neurology. He established a specialist cognitive disorders clinic, which acts as a tertiary referral service for young onset and rare dementias. Martin's clinical research interests are in the degenerative dementias, particularly familial disease, and more recently in general cognitive impairment in systemic disease and multimorbidity. He established the Queen Square Dementia Research Centre and has served as the editor of the Journal of Neurology, Neurosurgery and Psychiatry, President of the Association of British Neurologists, Director of the NIHR Clinical Research Network for Dementia and Neurodegenerative diseases (DeNDRoN), and Director of the NIHR Queen Square Dementia Biomedical Research Unit.



Professor Jane Rylett

Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Aging

Dr Jane Rylett was appointed as Scientific Director of the Canadian Institutes of Health Research (CIHR) Institute of Aging in 2019. She is also located in London, Canada and is a Distinguished University Professor at the University of Western Ontario and a Scientist in the Molecular Medicine Research Laboratories and Translational Neuroscience Group at Robarts Research Institute. Trained in Canada, England and Germany as a cellular and molecular neuroscientist, her laboratory studies the consequences of age-related changes in brain and neurodegenerative diseases. Dr. Rylett is recognized internationally for contributions to the field of cholinergic neurobiology and Alzheimer disease. She has served on Boards of Directors of the Alzheimer Societies of Canada and Ontario and on taskforces for international



endeavours for Alzheimer Disease research. She served as leader of the Canadian Consortium on Neurodegeneration in Aging (CCNA) Theme 1 – Prevention until 2019. Dr. Rylett is a Fellow of the Canadian Academy of Health Sciences.



**Professor
Jonathan Schott**

Professor of Neurology,
Dementia Research
Centre, UCL Institute
of Neurology


Jonathan Schott is Professor of Neurology at the Dementia Research Centre, UCL Institute of Neurology, and Honorary Consultant Neurologist at Queen Square. He co-leads the mental ageing programme of the MRC British 1946 birth cohort; is Clinical Advisor to the UK Dementia Research Institute; emeritus Chair of the ISTAART advisory council; and Chief Medical Officer for Alzheimer’s Research UK, Europe’s largest dementia research charity. His clinical practice and research (>280 papers, H-index 68) centre on the dementias, with particular interests in how clinical, cognitive and life course data, imaging and fluid biomarkers, and genetics can be used and combined to improve differential diagnosis and identify pre-symptomatic dementia.



Dr Eric Siemers

President, Siemers
Integration

Eric Siemers has over 25 years of experience in clinical trials of neurodegenerative disease. His research focus is on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases. Dr Siemers most recently served as a distinguished medical fellow for Eli Lilly and Company’s Alzheimer’s Disease Global Development Team, where he was responsible for the design and implementation of five large phase III clinical studies, in addition to playing a major collaborative role in two public-private partnership studies. Dr Siemers earned his medical degree from the Indiana University School of Medicine (US).



Dr Heather Snyder

Vice president, Medical & Scientific Relations at the Alzheimer's Association


Heather M. Snyder, Ph.D., is vice president, Medical & Scientific Relations at the Alzheimer's Association®. In this role, she oversees Association initiatives that accelerate innovative Alzheimer's research and provide opportunities for the global dementia community to connect and collaborate. Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. To increase knowledge about prevention and risk reduction, Dr. Snyder serves on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.



Professor Hilikka Soininen

Professor in Neurology, University of Eastern Finland

Hilkka Soininen, MD, PhD, professor in neurology, specialist in neurology with special expertise in memory diseases. She has worked as Professor in Neurology, University of Eastern Finland, Chief Physician, Neurocenter, neurology Kuopio University Hospital, Finland. The current focus of research is improving diagnosis, therapy and prevention of Alzheimer's disease and promote brain health. She is an author of over 700 peer reviewed international publications and supervisor of over 40 PhD theses. She has received research funding e.g. from Academy Finland and European Union programs. She has participated as PI of UEF in numerous national and international / EU projects and consortia such as CAIDE, FINGER, ADDNeuroMed, PREDICTAD, LipiDiDiet, EMIF, HATICE, VPH-DARE, PredictND consortia. Currently she is also involved in FINNGEN project and European and global genetic consortia.



Professor Reisa Sperling

Co-principal investigator of the Harvard Aging Brain Study in Boston


Reisa Sperling is co-principal investigator of the Harvard Aging Brain Study in Boston (US). She is a neurologist focused on the detection and treatment of Alzheimer's disease, even before clinical symptoms are evident. Her research uses neuroimaging and cognitive tests to understand the aging brain and the earliest changes associated with Alzheimer's disease. She is a professor in neurology at Harvard Medical School, director of the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, and director of neuroimaging for the Massachusetts ADRC at Massachusetts General Hospital.



Dr Rudolph Tanzi

Director of the Genetics and Aging Research Unit and Professor of Neurology, Harvard Medical School

Dr Rudolph Tanzi is the Director of the Genetics and Aging Research Unit, Co-Director of the McCance Center for Brain Health, Co-Director of the MassGeneral Institute for Neurodegenerative Disease, and Vice-Chair of Neurology (Research), at Massachusetts General Hospital, and the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. Dr Tanzi discovered the first three Alzheimer's disease genes and the first neuroinflammation-related Alzheimer's gene, CD33. He is developing therapies for treating and preventing AD using human his laboratory's brain organoid models. Dr Tanzi has published nearly 600 papers, received numerous awards, including the Metropolitan Life Award, Potamkin Prize, Smithsonian American Ingenuity Award, and was one of the TIME100 Most Influential People in the World. Dr Tanzi is a New York Times bestselling author, who co-authored "Decoding Darkness" "Super Brain", "Super Genes", and "The Healing Self" with Deepak Chopra. He has also hosted three PBS shows and made numerous appearances on network and cable news and medical television shows. In his spare time, he plays keyboards for Joe Perry, Aerosmith and other musicians.



Dr Martin Traber

Global Medical Lead for Alzheimer's Disease, Roche


Dr Martin Traber is a bio-pharmaceutical professional with more than 15 years of experience in clinical development and medical affairs. Neurosciences are the focus including Alzheimer's Disease, Multiple Sclerosis, and Spinal Muscular Atrophy. His involvement with Alzheimer's Disease goes back to the first monoclonal antibodies investigated, namely bapineuzumab, for which he was running the clinical trials in Switzerland at that time. Today at Roche, Martin serves as the Global Medical Lead for Alzheimer's Disease supporting the late-stage investigational anti-amyloid drugs gantenerumab, crenezumab and the anti-tau drug semorinemab, as well as our diagnostic solutions including the EMA approved Elecsys® CSF assays.



Professor Wiesje van der Flier

Professor and head of clinical research at Alzheimer center Amsterdam at Amsterdam UMC

Wiesje van der Flier (1975) is full professor and head of clinical research at Alzheimer center Amsterdam at Amsterdam UMC, the Netherlands, where she works since 2004. She studied neuropsychology at the University of Utrecht. In addition, she is clinical epidemiologist. She leads the Amsterdam Dementia Cohort, an ongoing memory-clinic based cohort including over 6000 patients with deep phenotyping (MRI, EEG, CSF biomarkers, and PET) and linked biobank (blood, DNA, CSF). The Amsterdam Dementia Cohort is at the basis of many of the studies performed at the VUmc Alzheimer center. Van der Flier has been (co)promotor of >20 theses and is currently supervising ~10 PhD projects. Van der Fliers main research areas are looking for the origin of AD, diagnosis&prognosis, and intervention&prevention. Together with colleague Philip Scheltens, she has written a book, het Alzheimermysterie, which was published by the Arbeiderspers.



Professor Linda Jo Van Eldik

Director of the Sanders-Brown Center on Aging and the NIA-funded Alzheimer's Disease Research Center, University of Kentucky


Linda Jo Van Eldik, PhD, is Director of the Sanders-Brown Center on Aging and the NIA-funded Alzheimer's Disease Research Center, Co-Director of the Kentucky Neuroscience Institute, a University Research Professor, and Professor of Neuroscience at the University of Kentucky in Lexington KY. She received her PhD in Microbiology and Immunology from Duke University, and did postdoctoral research in Virology and Cell Biology at Rockefeller University. She joined the faculty at Vanderbilt University Medical Center in 1981, where she rose to the rank of Professor of Pharmacology and Cell Biology. From 1994 – 2010, she was Professor of Cell and Molecular Biology, Co-Director of the University Center for Drug Discovery and Chemical Biology, and Associate Director of the Alzheimer's Disease Center at Northwestern University in Chicago. Dr Van Eldik's research program focuses on dysregulated neuroinflammation in CNS disorders, identifying potential points of intervention, and developing new small molecule drug candidates to slow the progression of cognitive impairment and neurodegeneration. In collaborative efforts at the biology-chemistry interface, she has shepherded a set of small molecule compounds from design and synthesis, through IND-enabling preclinical development, with three in phase I human clinical trials.



Professor Bruno Vellas

Chairman of the Toulouse Gerontopole, and Head of the Alzheimer Disease Clinical Research Centre

Professor Vellas (MD, PhD) is currently Chairman of the Toulouse Gerontopole, Head of the Department of Internal Medicine and Geriatrics at Toulouse University Hospital, and Head of the Alzheimer Disease Clinical Research Centre, University of Toulouse and a member of INSERM (National Institute of Medical Research) 1027 Unit on Aging. He is also Past-President of the IAGG (International Association of Gerontology and Geriatrics). Prof. Vellas obtained his medical degree (MD) and PhD from the University Paul Sabatier, Toulouse, and for more than 20 years now he has been involved in large trial on Alzheimer's disease and on Frailty. He has published over 560 articles in the field and especially on Alzheimer's and disease modifying treatment. Prof. Vellas is the founder



of the E.A.D.C. (European Alzheimer's Disease Consortium). He is associate editor of the JPAD (Journal of Prevention of Alzheimer's Disease), principal investigator of large international trials in the field including GuidAge, MAPT trial and part of large European Funded Program.



George Vradenburg

Co-Chair,
Davos Alzheimer's
Collaborative


George Vradenburg serves as Co-Chair of the Davos Alzheimer's Collaborative, a coalition focused on driving global scientific, business, policy and financial coordination in Alzheimer's preparedness, co-convened in January 2020 by the Global CEO Initiative on Alzheimer's Disease (CEOi) and the World Economic Forum. In this role, George provides general oversight and advocacy and works to ensure the Collaborative remains sustainable and action-oriented. George is the Chairman and Co-Founder of UsAgainstAlzheimer's (UsA2), a disruptive and catalytic force committed to stopping Alzheimer's by 2020. In 2011, the United States Secretary of the Department of Health and Human Services named George to serve on the National Alzheimer's Advisory Council on Research, Care and Services for the first-of-its-kind National Alzheimer's Strategic Plan. George received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. from Harvard Law School, cum laude.



Professor Andrew Welchman

Head of Neuroscience
and Mental Health at
the Wellcome Trust

Andrew Welchman is Head of Neuroscience and Mental Health at the Wellcome Trust and Professor of Neural Intelligence at the University of Cambridge. He has over 20 years of research experience in academia, and is an internationally recognised authority in the use of brain imaging and AI to understand the computations and functions of the human brain. He has worked in the UK and Germany and run several large international research consortia. At Wellcome he directs the funding strategy for a broad £500M portfolio in brain sciences and was central to the ideas that underpin Wellcome's new long term focus on mental health. He has broad interests in biomedical science, the future of innovation, and how foundations can use their independence and creativity to shape discovery. He regularly



engages across disciplines and sectors, working with other international funding agencies, government bodies and multinational companies. He is a Trustee of The India Alliance (in partnership with the Government of India), The Royal College of Ophthalmologists, and an advisor to BBC Children In Need's A Million and Me initiative focused on young people's mental health.



Professor Henrik Zetterberg

Professor of
Neurochemistry,
University of
Gothenburg

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg, Sweden. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and leads the UK DRI Fluid Biomarker Laboratory at UCL. His main research focus and clinical interest are fluid biomarkers for brain diseases, Alzheimer's disease in particular. He has published more than 1300 scientific articles and received numerous awards."

The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

worlddementiacouncil.org

© 2020 World Dementia Council
UK charity registration number: 1170743

Cover image editorial credit: Shutterstock.com

